Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
PERINDOPRIL ERBUMINE
NORA PHARMA INC
C09AA04
PERINDOPRIL
2MG
TABLET
PERINDOPRIL ERBUMINE 2MG
ORAL
100
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178001; AHFS:
CANCELLED POST MARKET
2022-07-25
_Priva-PERINDOPRIL ERBUMINE _ _Page 1 of 55 _ PRODUCT MONOGRAPH PR PRIVA-PERINDOPRIL ERBUMINE PERINDOPRIL ERBUMINE TABLETS, USP 2 MG, 4 MG AND 8 MG ANGIOTENSIN CONVERTING ENZYME INHIBITOR NORA PHARMA INC. 1565, Lionel-Boulet Boul. Varennes, Québec J3X 1P7 CONTROL NUMBER: 264075 DATE OF PREPARATION: May 31, 2022 _Priva-PERINDOPRIL ERBUMINE _ _Page 2 of 55 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ...................................................................................... 5 ADVERSE REACTIONS ...................................................................................................... 13 DRUG INTERACTIONS ...................................................................................................... 20 DOSAGE AND ADMINISTRATION .................................................................................. 22 OVERDOSAGE ..................................................................................................................... 24 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 25 STORAGE AND STABILITY .............................................................................................. 28 SPECIAL HANDLING INSTRUCTIONS ............................................................................ 28 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 29 PART II: SCIENTIFIC INFORMATION ................................................................................... 30 PHARMACEUTICAL INFORMATION ......................................... Διαβάστε το πλήρες έγγραφο